2021

  1. [Related Article]
    Lee J, Kim EJ, Lee JG, Kim BS, Huh KH, Kim MS, Kim SI, Kim YS, Joo DJ, “Clinical impact of serum bilirubin levels on kidney transplant outcomes”, Scientific Reports. 2021; 11, 6889
  2. [Related Article]
    TW Kim, Y Kim, W Jung, DE Kim, H Keum, Y Son, S Jon, “Bilirubin nanomedicine ameliorates the progression of experimental autoimmune encephalomyelitis by modulating dendritic cells”, Journal of Controlled Release, Volume 331, 10 March 2021, Pages 74-84. (IF: 7.633)

2020

  1. [Related Article]
    Terry D. Hinds Jr., Justin F. Creeden, Darren M. Gordon, Donald F. Stec, Matthew C. Donald and David E. Stec, “Bilirubin Nanoparticles Reduce Diet-Induced Hepatic Steatosis, Improve Fat Utilization, and Increase Plasma β-Hydroxybutyrate”, Front. Pharmacol.(IF: 4.418)
  2. [Review Article]
    Libor Vitek, M.D., Ph.D, and Claudio Tiribelli, M.D., Ph.D, “Bilirubin, Intestinal Integrity, the Microbiome, and Inflammation”, N ENGL J MED 383;7, August 13, 2020. (IF: 70.670)
  3. [Related Article]
    H Keum, TW Kim, Y Kim, C Seo, Y Son, J Kim, D Kim, W Jung, CH Whang, S Jon*, “Bilirubin nanomedicine alleviates psoriatic skin inflammation by reducing oxidative stress and suppressing pathogenic signaling”, Journal of Controlled Release, 2020, 325:359-369. (IF: 7.633)
  4. [Related Article]
    DY Lee, S Kang, Y Lee, JY Kim, D Yoo, W Jung, S Lee, YY Jeong, K Lee, S Jon*, “PEGylated Bilirubin-coated Iron Oxide Nanoparticles as a Biosensor for Magnetic Relaxation Switching-based ROS Detection in Whole Blood”, Theranostics, 2020, 10 (5). (IF: 8.712)

2019

  1. [Related Article]
    Y Lee, K Sugihara, MG Gillilland, S Jon, N Kamada, JJ Moon*, “Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis”, Nature Materials,19, 118-126. (IF: 38.887)

2018

  1. [Related Article]
    PAreek S, Zhang Mao, Trujillo-Ocampo A, Kim J, Jon S and Im JS, Bilirubin Nanoparticle as an anti-inflammatory therapy for graft versus host disease”, J Immunol. 1 May 2018, Vol. 200 (1 Supplement) (IF: 4.718)
  2. [Related Article]
    Lee S, Lee Y, Kim H, Lee DY and Jon S*, “Bilirubin Nanoparticle-Assisted Delivery of a Small Molecule-Drug Conjugate for Targeted Cancer Therapy”, Biomacromolecules. 2018; 19, 6, 2270-2277 (IF: 5.246)
  3. [Related Article]
    Lee Y, Lee S and Jon S*, “Biotinylated Bilirubin Nanoparticles as a Tumor Microenvironment-responsive Drug Delivery System for Targeted Cancer Therapy”, Adv. Science. 2018; 5, 1800017 (IF: 9.034)

2017

  1. [Related Article]
    Lee DY, Kim JY, Lee S, Miao W, Kim HS, Min JJ and Jon S*, “Black pigment gallstone-inspired platinum-chelated bilirubin nanoparticles for combined photoacoustic imaging and photothermal therapy of cancers”, Angew. Chem. Int. Ed. 2017; 56(44): 13684-13688. (IF: 11.994) (Oct 23; Epub Sep 4)
  2. [Related Article]
    Kim DE,1 Lee Y,1 Kim M, Lee S, Jon S* and Lee SH*, “Bilirubin nanoparticles ameliorate allergic lung inflammation in a mouse model of asthma”, Biomaterials 2017; 140, 37-44. (IF: 8.402) (Epub Jun 12) (1Equal contribution)
  3. [Related Article]
    Kim MJ, Lee Y, Jon S and Lee DY*, “PEGylated bilirubin nanoparticle as an anti-oxidative and anti-inflammatory demulcent in pancreatic islet xenotransplantation”, Biomaterials 2017; 133: 242-252. (IF: 8.402) (Jul, Epub Apr 18)
  4. [Related Article]
    Kim JY, Lee DY, Kang S, Miao W, Kim H, Lee Y and Jon S*, “Bilirubin nanoparticle preconditioning protects against hepatic ischemia-reperfusion injury”, Biomaterials 2017; 133: 1-10. (IF: 8.402) (Jul, Epub Apr 12)

2016

  1. [Related Article]
    Lee Y, Lee S, Lee DY, Yu B, Miao W and Jon S*, “Multi-stimul-responsive bilirubin nanoparticles for anticancer therapy”, Angew. Chem. Int. Ed. 2016: 55, 1-6 (Selected as a Very Important Paper(VIP))
  2. [Related Article]
    Lee Y, Kim H, Kang S, Lee J, Park J and Jon S*, “Bilirubin Nanoparticles as a Nanomedicine for Anti-inflammation Therapy”, Angew. Chem. Int. Ed. 2016: 55(26), 7460-3. (IF: 11.709) (Jun 20)